Abstract 397P
Background
Chronic hepatitis B infection is one of the leading causes of hepatocellular carcinoma (HCC) worldwide. Despite the endorsement of semi-annual ultrasonography as HCC surveillance method by international societies in at risk population, the accurate prediction of HCC risk is important for public policy strategy in a limited-resource country. Thus, we aim to develop the scoring systems, which are individualized surveillance strategy and cost-effectiveness to assess the risk of HCC in patients with chronic hepatitis B.
Methods
This retrospective cohort study was conducted to develop a risk estimate model of HCC in chronic hepatitis B (CHB) patients. Our prediction model was derived from data obtained in 2,208 CHB patients from Chulabhorn Hospital, Thailand. (Follow-up period: 2011-2017). Forward stepwise multivariable parametric regression model was applied to obtain coefficients for each predictor. Model input included age, sex, liver cirrhosis, cigarette smoking, alcohol consumption, diabetes mellitus, body mass index, serum HBV DNA level, HBeAg status, alanine aminotransferase, aspartate aminotransferase (AST), alpha-fetoprotein and AST to platelet ratio index. Receiver operating characteristic curves were used to assess discriminatory accuracy of the model.
Results
During a median follow-up of 6.67 years, 20 cases of HCC were newly diagnosed. Age and liver cirrhosis were statistical significant independent predictors of HCC risk. In the bootstrap simulation (1000 random samplings), the corrected c-index was 0.75 (0.58-0.91). The HCC risk was calculated from the following formula: Age (<50 year = 0; 50-59 year = 1; ≥ 60 year = 2) + Cirrhosis (Yes = 4; No = 0). A 6-point risk score could predict HCC risk at 10 years, ranging from 1.95%, 18.29% and 56.96% in low- (score 0-2), medium- (score 4-5) and high-risk group (score 6).
Conclusions
A simple prediction score constructed from routine clinical and laboratory parameters are accurate in predicting HCC development in Thai patients with CHB infection. Individualized HCC surveillance strategy including surveillance interval and/or alternative surveillance test could be reasonable and cost effectiveness based on our risk scoring. Future prospective validation study is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Teerapat Ungtrakul.
Funding
Chulabhorn Royal Academy.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
107P - The efficacy of adjuvant chemotherapy according to the risk classification of recurrence based on the systemic inflammatory markers in patients with colorectal cancer liver metastases
Presenter: Masatsune Shibutani
Session: Poster display session
Resources:
Abstract
108P - Influence of liver metastasis locations on overall survival in patients with colorectal cancer
Presenter: Takayuki Sone
Session: Poster display session
Resources:
Abstract
109P - 18F-FDG PET/CT textural features as predictors of outcomes in patients with primary advanced colorectal cancer
Presenter: Jing Yang
Session: Poster display session
Resources:
Abstract
110P - D3 lymph node dissection may be necessary in clinical stage I right colon cancer
Presenter: Woong Bae Ji
Session: Poster display session
Resources:
Abstract
111P - Is preoperative chemoradiotherapy necessary for all patients with upper rectal cancer: One center retrospective study
Presenter: Jasur Madyarov
Session: Poster display session
Resources:
Abstract
112P - A retrospective analysis of the association between perioperative, post adjuvant carcinoembryonic antigen level and prognosis in stage III colorectal cancer
Presenter: Ryotaro Kozuki
Session: Poster display session
Resources:
Abstract
113P - Dicer contributes to chemoresistance in colorectal cancer via regulating a set of miRNAs and their downstream mRNAs
Presenter: Liang-Yi Hung
Session: Poster display session
Resources:
Abstract
114P - Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial
Presenter: Jun Zhu
Session: Poster display session
Resources:
Abstract
115P - Expression of Ki-67 as a prognostic factor in patients with colorectal cancer
Presenter: Kuantkan Zhabagin
Session: Poster display session
Resources:
Abstract
116P - Clinical significance and converionrate relevance of RAS genetic mutation analysis for unresectable colorectal liver metastases: A single-center retrospective study
Presenter: Meiling Ji
Session: Poster display session
Resources:
Abstract